DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07633639

RecruitingPhase NA

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

The Efficacy and Safety of Adjuvant GLP-1 Receptor Agonist Therapy Following Metabolic Bariatric Surgery in Chinese Patients With Obesity: A Prospective, Monocentric, Stratified Randomized Controlled Trial

Assets

Mazdutide / Semaglutide / Tirzepatide

Listed sites

1

Recruiting sites

1

Enrollment

200

estimated

Study population

Bariatric Surgery, Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Percentage of weight loss

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07633639
Org study ID2026-CJH-OBE

Timeline

Milestones

Study start2026-05-01actual
Study first posted2026-06-08actual
Last update posted2026-06-08actual
Primary completion2028-05-01estimated
Study completion2028-05-01estimated

Assets

Investigational agents

MazdutideSemaglutideTirzepatide

Study populations

Who this study enrolls

Bariatric SurgeryObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).

2. obesity:BMI ≥30 kg/m².

3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.

4. Age range: 18-60 years (inclusive).

5. Informed consent: Willing participation with documented consent.

Exclusion criteria

1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.

2. Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.

3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).

4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.

5. Significant comorbidities:

5.1Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR <30 mL/min/1.73m²). 5.2Active malignancy (except non-melanoma skin cancers). 5.3Autoimmune disorders requiring immunosuppression. 5.4Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).

Endpoints (27)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
8
Cardiometabolic biomarkers
5
Weight & body composition
4
Glycemic / diabetes
4
MASH / liver
3
Renal / kidney
3

Weight & body composition

4 endpoints
Primary/protocol endpoint

Percentage of weight loss.

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Weight in kilograms

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Waist circumference in centimeters

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Visceral fat area

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Glycemic / diabetes

4 endpoints
Secondary/protocol endpoint

Fasting blood glucose

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Average blood glucose from continuous glucose monitoring

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Postprandial 2-hour blood glucose

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

HbA1c

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

MASH / liver

3 endpoints
Secondary/protocol endpoint

Alanine Aminotransferase(ALT)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Aspartate Aminotransferase(AST)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Liver Stiffness Measurement(LSM)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Renal / kidney

3 endpoints
Secondary/protocol endpoint

Serum creatinine

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Glomerular filtration rate

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

ratio, improvement

Secondary/protocol endpoint

urine microalbumin-to-creatinine ratio (ACR)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

ratio, improvement

Cardiometabolic biomarkers

5 endpoints
Secondary/protocol endpoint

Blood pressure

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Total cholesterol

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Low-Density Lipoprotein(LDL)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

Triglycerides

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint

uric acid(UA)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Other (unclassified)

8 endpoints
Secondary/protocol endpoint/low confidence

Hip circumference in centimeters

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint/low confidence

Urinary microalbumin

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint/low confidence

body fat percentage(BFP)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint/low confidence

Muscle mass in kilograms

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint/low confidence

Body fat percentage

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint/low confidence

lean body mass (LBM)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint/low confidence

lean body mass percentage (LBMP)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Secondary/protocol endpoint/low confidence

Controlled Attenuation Parameter(CAP)

Time frame:Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.